Corporate Support

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

17.9 (0.72%)


  • STI Straits Times Index
    17.9 (0.72%)
  • KLCI FTSE Bursa Malaysia KLCI
    -9.3 (-0.62%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    25.7 (0.11%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    5.4 (0.17%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    -13.8 (-0.06%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    -16.1 (-0.33%)
    Index delayed 10 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market


NYSE American Market

  • Volume: 1,194.5M
  • Value: 1,084.8M
  • Rise: 187
  • Fall: 107
  • Unch: 488

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Sembcorp Marine0.151+0.006
Jiutian Chemical0.046+0.001
Vicplas Intl0.455+0.015
Medtecs Intl1.280+0.100
Rex Intl0.149+0.004
NetLink NBN Tr0.950-0.015
QT Vascular0.008+0.001

World Indices

World Indices
Name Last Change
Nasdaq 10,633.0 -330.6
HSI 23,742.5
HSCEI 9,558.8
Jakarta 4,918.0
Nikkei 225 23,346.5
SSE Comp 3,279.7
Shanghai A 3,437.3
Shanghai B 250.0
KOSPI 2,333.2

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

News - Detailed News Story


Stock Chart
Last Done 0.156
Change +0.002 (+1.30%)
Volume 3,693.5
Range 0.152 - 0.159


Stock Chart
Last Done 0.315
Change +0.010 (+3.28%)
Volume 3,284.5
Range 0.295 - 0.325

Hyphens Pharma

Stock Chart
Last Done 0.455
Change +0.070 (+18.18%)
Volume 13,958
Range 0.385 - 0.470

IX Biopharma

Stock Chart
Last Done 0.240
Change +0.015 (+6.67%)
Volume 16,476.9
Range 0.225 - 0.245


Stock Chart
Last Done 79.970
Change - (-)
Volume -
Range - - -


Stock Chart
Last Done 8.980
Change +0.080 (+0.90%)
Volume 2,553.7
Range 8.850 - 9.010

Covid-19 exposes SGX's lack of biopharmaceutical issuers

02 Jul 2020 09:00

By Angela Tan

SINGAPORE-BASED biotech Cennerv Pharmaceuticals tried twice to list on the Singapore Exchange (SGX) but was forced to withdraw its initial public offer (IPO) due to weak demand.

At that time, a clearly disappointed chief executive officer Anil Ratty told shareholders in a statement:"The insufficient demand for placement shares at a suitable price meant that this IPO at a low price in the Singapore capital market would have adversely affected all future fundraising in the market, a very critical step envisaged for ongoing growth in the post IPO period."

Dr Ratty told The Business Times then that he was still eyeing an IPO, but in other markets.

The story has a sad, familiar ring to it. It illustrates the challenges facing SGX as it seeks to attract biopharmaceutical firms to list here.

ShareInvestor subscribers have full access to this article. ShareInvestor subscriber, please login to read the 27 remaining paragraph(s).

Source: Business Times

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.
We use Cookies. By continuing to use this webite, you will be agreeing to our Privacy Policy, Terms and Conditions and Cookie Policy.